ReviewAdvances in experimental medicine and biology2021
Naturally Occurring SGLT2 Inhibitors: A Review.
Review in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden.Toxicology reports · 2026Review
- From Bench to Bedside in Precision Medicine: Diabetes Mellitus and Peri-Implantitis Clinical Indices with a Short-Term Follow-Up: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With an increasing incidence of diabetes mellitus globally due to various factors, including unhealthy lifestyle, there is a need for developing novel drugs for the management of diabetes. This chronic metabolic disorder results in high blood glucose levels due to the body's inability to reduce the concentration of glucose. The decreased secretion of insulin and increased resistance to insulin action contribute to the development of diabetes mellitus. There have been efforts to target pathways involved in the metabolism of blood glucose. It seems that most of the currently applied antidiabetic medications are associated with unwanted side effects. Hence, it appears that plant-derived chemicals can be considered as potential candidates in the management of diabetes. Sodium-glucose cotransporter inhibitors (SGLT2i) are synthetic hypoglycemic medications approved for managing patients with diabetes in lowering blood glucose. SGLT2i reduces blood glucose concentration by enhancing its urinary excretion and inhibition of its absorption through the kidney. It has been demonstrated that some of the naturally occurring nutraceutical agents can imitate the action of SGLT2i and, consequently, diminish the level of blood glucose. At the present review, we have discussed the phytochemicals that act like SGLT2i to decrease blood glucose level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.